Cartesian Therapeutics
RNAC
29 hedge funds and large institutions have $106M invested in Cartesian Therapeutics in 2016 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
81% more funds holding
Funds holding: 16 → 29 (+13)
1% more capital invested
Capital invested by funds: $105M → $106M (+$1.32M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.71M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.78M |
| 3 |
Goldman Sachs
New York
|
+$381K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$145K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.73M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.33M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$656K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$506K |
| 5 |
Millennium Management
New York
|
-$358K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $6K | +$5.47K | +14 | New |
|
27
Bank of America
Charlotte,
North Carolina
| $3K | +$2.35K | +6 | New |
|
28
BNP Paribas Financial Markets
Paris,
France
| $2.61K | +$2.35K | +6 | New |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1.17K | +3 | New |
|
|
SSA
30
Schonfeld Strategic Advisors
New York
| – | -$656K | -1,562 | Closed |
|
|
31
Marshall Wace
London,
United Kingdom
| – | -$506K | -1,207 | Closed |
|
|
32
Millennium Management
New York
| – | -$358K | -852 | Closed |
|
RNAC Hedge Fund Activity: Q3 2016 in Review
29 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2016, worth a combined $106M — up 1.3% from $105M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RNAC positions and 3 closed out — a net gain of 14 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $3.71M. The largest seller was UBS Group, cutting an estimated $3.73M.
- 29 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2016, up from 16 in Q2 2016.
- Funds reported $106M of Cartesian Therapeutics stock for Q3 2016, up 1.3% quarter-over-quarter.
- 17 funds opened new Cartesian Therapeutics positions in Q3 2016 and 3 closed out, a net change of +14 holders.
- The largest Cartesian Therapeutics buyer in Q3 2016 was Sphera Funds Management, an estimated $3.71M added.
- The largest Cartesian Therapeutics seller in Q3 2016 was UBS Group, an estimated $3.73M sold.
Based on aggregated 13F filings for Q3 2016.